GregoryEversonMD
Gastroenterology • Greenwood Village, COHepatology & Liver Transplantation
CEO CMO HepQuant LLC
Dr. Everson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5251 DTC Parkway
Suite 300
Greenwood Village, CO 80111Phone+1 303-923-2147
Education & Training
University of ColoradoFellowship, Gastroenterology, 1979 - 1981
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 1976 - 1979
Weill Cornell MedicineClass of 1976
Certifications & Licensure
CO State Medical License 1979 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- Fellow of the American Society of Transplantation AST, 2010
- Fellow of the American Association for the Study of Liver Disease AASLD, 2010
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Start of enrollment: 2000 Jun 01
- Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation Start of enrollment: 2005 Sep 01
- HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 630 citationsLedipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis
Gastroenterology. 2015-09-01 - 42 citationsBile acid synthesis in cultured human hepatoblastoma cells.M Axelson, B Mörk, Gregory T. Everson
The Journal of Biological Chemistry. 1991-09-25 - 266 citationsEfficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C☆K. Rajender Reddy, Teresa L. Wright, Paul J. Pockros, Mitchell L. Shiffman, Gregory T. Everson
Hepatology. 2001-02-01
Press Mentions
HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117April 4th, 2019- HepQuant Appoints Sean Bundy Director of Regulatory & Quality AffairsAugust 2nd, 2018
2015 AST FAST DesigneesMay 21st, 2015
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
